Loading
ESCORT-1st is China's first-line immunotherapy trial for squamous oesophageal cancer, one of five that together made chemo-immunotherapy the global standard.
ESCORT-1st, trial NCT03691090 sponsored by Jiangsu Hengrui and published in JAMA in 2021, is China's first-line immunotherapy trial for advanced oesophageal squamous cell carcinoma, one of five concordant trials that together made chemo-immunotherapy the global standard. It randomised 596 patients to camrelizumab or placebo with paclitaxel and cisplatin and met its primary overall survival endpoint, confirmed at the final analysis in 2024; camrelizumab is approved in China for the disease but not in the United States, and the later ESCORT-NEO trial showed neoadjuvant camrelizumab plus chemotherapy raises pathologic complete response in resectable disease. OnCo links it to oesophageal cancer, PD-1 as a target, camrelizumab, Jing Huang and Rui-Hua Xu. Whether Chinese PD-1 antibodies reach patients outside China for this indication is the open question.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Shares Camrelizumab, Jiangsu Hengrui Pharmaceuticals, Immune checkpoint inhibitors.
Shares Camrelizumab, Jiangsu Hengrui Pharmaceuticals, Immune checkpoint inhibitors.
Shares Camrelizumab, Jiangsu Hengrui Pharmaceuticals, Immune checkpoint inhibitors.
Shares Camrelizumab, Jiangsu Hengrui Pharmaceuticals, Immune checkpoint inhibitors.
Shares Camrelizumab, Jiangsu Hengrui Pharmaceuticals, Immune checkpoint inhibitors.
Shares Rui-Hua Xu, Oesophageal cancer, Immune checkpoint inhibitors.
Shares Jiangsu Hengrui Pharmaceuticals, Oesophageal cancer, Immune checkpoint inhibitors.